Literature DB >> 22946944

Multiregional clinical trials: Japanese perspective on drug development strategy and sample size for Japanese subjects.

Yuki Ando1, Yoshiaki Uyama.   

Abstract

Multiregional clinical trials including Japanese subjects are playing a key role in new drug development in Japan. In addition to the consideration of differences in intrinsic and extrinsic ethnic factors, deciding the sample size of Japanese subjects is an important issue when a multiregional clinical trial is intended to be used for Japanese submission. Accumulated experience suggests that there are several points to consider, such as the basic principles described in the guidance document, drug development strategy, trial phase, and disease background. The difficulty of interpreting the results of Japanese trials should also be considered.

Mesh:

Year:  2012        PMID: 22946944     DOI: 10.1080/10543406.2012.701581

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  4 in total

1.  Population/regional differences in efficacy of 3 drug categories (antidiabetic, respiratory and psychotropic agents) among East Asians: A retrospective study based on multiregional clinical trials.

Authors:  Kimie Sai; Akiomi Yoshida; Tadaaki Hanatani; Takuya Imatoh; Masahiro Takeuchi; Mamoru Narukawa; Hiroshi Watanabe; Yoshiaki Uyama; Yoshiro Saito
Journal:  Br J Clin Pharmacol       Date:  2019-03-28       Impact factor: 4.335

2.  Current Status and Open Issues Concerning Global Clinical Trials (GCTs) in Japan and East Asia.

Authors:  Koichi Miyazaki; Yasunori Sato; Hideki Hanaoka; Yoshiaki Uyama
Journal:  Clin Transl Sci       Date:  2017-07-04       Impact factor: 4.689

3.  Factors Affecting Drug-Development Strategies in Asian Global Clinical Trials for Drug Approval in Japan.

Authors:  Kunihito Asano; Yoshiaki Uyama; Masahiro Tohkin
Journal:  Clin Transl Sci       Date:  2017-11-15       Impact factor: 4.689

Review 4.  Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles.

Authors:  K Venkatakrishnan; C Burgess; N Gupta; A Suri; T Takubo; X Zhou; D DeMuria; M Lehnert; K Takeyama; S Singhvi; A Milton
Journal:  Clin Transl Sci       Date:  2016-02-05       Impact factor: 4.689

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.